# Ellen M. Ginzler

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ellen-m-ginzler/

## Facts

| Field | Value |
| --- | --- |
| Citations | 38,408 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 72 |
| i10-index | 142 |
| OpenAlex ID | https://openalex.org/A5069100301 |
| ORCID iD | https://orcid.org/0000-0002-7306-7375 |
| Works | 249 |

## Researcher papers

Showing 12 of 22.

- [Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus](https://scholariq.org/papers/derivation-and-validation-of-the-systemic-lupus-international-collaborating/)
- [Derivation of the sledai. A disease activity index for lupus patients](https://scholariq.org/papers/derivation-of-the-sledai-a-disease-activity-index-for-lupus-patients/)
- [The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus](https://scholariq.org/papers/the-development-and-initial-validation-of-the-systemic-lupus-international/)
- [The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited](https://scholariq.org/papers/the-classification-of-glomerulonephritis-in-systemic-lupus-erythematosus/)
- [A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus](https://scholariq.org/papers/a-phase-iii-randomized-placebo-controlled-study-of-belimumab-a-monoclonal/)
- [The classification of glomerulonephritis in systemic lupus erythematosus revisited](https://scholariq.org/papers/the-classification-of-glomerulonephritis-in-systemic-lupus-erythematosus-2/)
- [Mortality in systemic lupus erythematosus](https://scholariq.org/papers/mortality-in-systemic-lupus-erythematosus/)
- [Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis](https://scholariq.org/papers/mycophenolate-mofetil-or-intravenous-cyclophosphamide-for-lupus-nephritis/)
- [Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis](https://scholariq.org/papers/mycophenolate-mofetil-versus-cyclophosphamide-for-induction-treatment-of-lupus/)
- [The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus](https://scholariq.org/papers/the-reliability-of-the-systemic-lupus-international-collaborating-clinics/)
- [Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis](https://scholariq.org/papers/mycophenolate-versus-azathioprine-as-maintenance-therapy-for-lupus-nephritis/)
- [The frequency and outcome of lupus nephritis: results from an international inception cohort study](https://scholariq.org/papers/the-frequency-and-outcome-of-lupus-nephritis-results-from-an-international/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.